Jove
Visualize
お問い合わせ

関連する概念動画

Primary Distribution01:28

Primary Distribution

Primary distribution systems deliver electrical power from substations to consumers through various voltage classes, with 15-kV class voltages being predominant among U.S. utilities. Older 2.5- and 5-kV classes are being replaced by 15-kV primaries, while higher 25- to 34.5-kV classes are used in high-density urban areas and rural regions with long feeders. Three-phase, four-wire multigrounded systems are widely employed for balanced power delivery, using the neutral wire as a grounding point.
Secondary Distribution01:25

Secondary Distribution

Secondary distribution systems provide electrical energy at the utilization voltage levels from distribution transformers to customer meters. Typical secondary voltages in the United States include 120/240 V for residential use, 208Y/120 V for residential and commercial use, and 480Y/277 V for industrial and high-rise commercial use.
In residential areas, 120/240 V single-phase, three-wire service is commonly used for lighting, outlets, and large appliances. Urban areas with high-density loads...
Drug Distribution: Overview01:11

Drug Distribution: Overview

Drug distribution within the body is a dynamic process involving the movement of a drug in two directions across various compartments: from the bloodstream into tissues (tissue uptake) and from tissues back into the bloodstream (tissue release or redistribution). This process is passive and primarily driven by two variables: the concentration gradient between the bloodstream and the extravascular tissues and the drug's ability to cross the cell membrane.
Initially, the free drug in the...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Introduction to 50th anniversary celebration issue for circulation

Circulation·2000
Same author

: august 8, 2000

Circulation·2000
Same author

: august 1, 2000

Circulation·2000
Same author

July 25, 2000

Circulation·2000
Same author

July 11, 2000

Circulation·2000
Same author

July 4, 2000

Circulation·2000
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

Updated: Jul 7, 2026

A Converging Strategy for the Generation of a Virtually Sequenced cDNA Library from Unreferenced Pacific Oysters
12:14

A Converging Strategy for the Generation of a Virtually Sequenced cDNA Library from Unreferenced Pacific Oysters

Published on: June 13, 2019

オンラインでのみ配布: 1999年12月21日/28日

Willerson

    Circulation
    |December 22, 1999
    PubMed
    まとめ

    No abstract available in PubMed .

    さらに関連する動画

    The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
    05:57

    The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

    Published on: May 17, 2024

    Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
    07:15

    Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

    Published on: August 23, 2024

    関連する実験動画

    Last Updated: Jul 7, 2026

    A Converging Strategy for the Generation of a Virtually Sequenced cDNA Library from Unreferenced Pacific Oysters
    12:14

    A Converging Strategy for the Generation of a Virtually Sequenced cDNA Library from Unreferenced Pacific Oysters

    Published on: June 13, 2019

    The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
    05:57

    The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

    Published on: May 17, 2024

    Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
    07:15

    Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

    Published on: August 23, 2024